Integer Holdings Q3 Revenues Up 8.4% But EBITDA Guidance Misses; Q4 Sales Seen at $462.7M
Integer Holdings reported Q3 revenues of $467.7 million, up 8.4% year-on-year, while full-year EBITDA guidance missed analysts’ expectations significantly and full-year revenue guidance slightly undercut forecasts. Analysts project Q4 sales of $462.7 million, a 2.9% increase year-over-year, with adjusted EPS of $1.70 per share.
1. Q3 Performance and Guidance Miss
Integer Holdings delivered Q3 revenues of $467.7 million, marking an 8.4% year-on-year increase. However, its full-year EBITDA guidance fell well below analyst forecasts and revenue guidance came in slightly under expectations, raising caution ahead of Q4 results.
2. Q4 Analyst Expectations
Wall Street analysts anticipate Q4 revenue of $462.7 million, a 2.9% increase from the year-ago quarter, and adjusted earnings of $1.70 per share. This pace of growth would slow from the 11.1% revenue gain recorded in the same period last year.
3. Peer Q4 Results Provide Context
Haemonetics posted a 2.7% year-on-year revenue decline but beat estimates by 2.4%, while Inspire Medical Systems achieved 12.2% revenue growth, topping forecasts by 1.1%. Both peers saw share prices drop more than 10% after their results.
4. Sector Trends and Market Risks
Healthcare equipment and supplies stocks have underperformed, down 3.5% on average over the past month, whereas Integer Holdings shares have risen 2.9%. Potential tariff actions and an average analyst price target of $85.57 versus the current $87.67 share price may influence near-term trading.